Last quarter (Q ), Checkmate Pharmaceuticals's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Checkmate Pharmaceuticals's net income was $-15.87M. See Checkmate Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operating Expense	$ 63.17M	$ 61.47M	$ 36.90M	$ 28.89M	$ 20.99M
Operating Income	$ -63.17M	$ -61.47M	$ -36.90M	$ -28.89M	$ -20.99M
Net Non Operating Interest Income Expense	$ 66.00K	$ 100.00K	$ 79.00K	$ 197.00K	$ 180.00K
Other Income Expense	$ -35.00K	$ -35.00K	$ -83.00K	$ 400.00K	-
Pretax Income	$ -63.14M	$ -61.41M	$ -36.91M	$ -28.29M	$ -20.81M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -63.14M	$ -61.41M	$ -42.91M	$ -28.29M	$ -25.13M
Basic EPS	$ -2.92	$ -2.84	$ -4.49	$ -3.44	$ -3.06
Diluted EPS	$ -2.92	$ -2.84	$ -4.49	$ -3.44	$ -3.06
Basic Average Shares	$ 86.51M	$ 21.62M	$ 9.56M	$ 8.22M	$ 8.22M
Diluted Average Shares	$ 86.51M	$ 21.62M	$ 9.56M	$ 8.22M	$ 8.22M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 63.17M	$ 61.47M	$ 36.90M	$ 28.89M	$ 20.99M
Net Income From Continuing And Discontinued Operation	$ -63.14M	$ -61.41M	$ -36.91M	$ -28.29M	$ -20.81M
Normalized Income	$ -63.11M	$ -61.37M	$ -36.91M	$ -28.29M	$ -20.81M
Interest Expense	-	-	-	-	-
EBIT	$ -63.17M	$ -61.47M	$ -36.90M	$ -28.89M	$ -20.99M
EBITDA	$ -63.08M	$ -61.40M	$ -36.90M	$ -28.89M	$ -20.99M

Currency in USD

Checkmate Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing